Targeted Therapy in Mesotheliomas: Uphill All the Way
Author:
Bertoli Elisa1ORCID, De Carlo Elisa1, Bortolot Martina12, Stanzione Brigida1ORCID, Del Conte Alessandro1ORCID, Spina Michele1, Bearz Alessandra1ORCID
Affiliation:
1. Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy 2. Department of Medicine, University of Udine, 33100 Udine, Italy
Abstract
Mesothelioma (MM) is an aggressive and lethal disease with few therapeutic opportunities. Platinum-pemetrexed chemotherapy is the backbone of first-line treatment for MM. The introduction of immunotherapy (IO) has been the only novelty of the last decades, allowing an increase in survival compared to standard chemotherapy (CT). However, IO is not approved for epithelioid histology in many countries. Therefore, therapy for relapsed MM remains an unmet clinical need, and the prognosis of MM remains poor, with an average survival of only 18 months. Increasing evidence reveals MM complexity and heterogeneity, of which histological classification fails to explain. Thus, scientific focus on possibly new molecular markers or cellular targets is increasing, together with the search for target therapies directed towards them. The molecular landscape of MM is characterized by inactivating tumor suppressor alterations, the most common of which is found in CDKN2A, BAP1, MTAP, and NF2. In addition, cellular targets such as mesothelin or metabolic enzymes such as ASS1 could be potentially amenable to specific therapies. This review examines the major targets and relative attempts of therapeutic approaches to provide an overview of the potential prospects for treating this rare neoplasm.
Reference181 articles.
1. Sauter, J.L., Bueno, R., Dacic, S., Gill, R.R., Husain, A.N., Kadota, K., Ladanyi, M., Nowak, A., and Schmitt, F. (2021). WHO Classification of Tumors Editorial Board, Lyon IARC Press. [5th ed.]. 2. Marsili, D., Terracini, B., Santana, V.S., Ramos-Bonilla, J.P., Pasetto, R., Mazzeo, A., Loomis, D., Comba, P., and Algranti, E. (2016). Prevention of Asbestos-Related Disease in Countries Currently Using Asbestos. Int. J. Environ. Res. Public Health, 13. 3. International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes;Grosse;Lancet Oncol.,2014 4. Reflecting real-world patients with mesothelioma in research: An interim report of baseline characteristics from the ASSESS-meso cohort;Conway;ERJ Open Res.,2023 5. Malignant pleural mesothelioma: A population-based study of survival;Milano;J. Thorac. Oncol.,2010
|
|